Paradigm to seek FDA approval for epidermolysis bullosa treatment
Paradigm Therapeutics is planning to seek U.S. Food and Drug Administration (FDA) approval for the experimental cream SD-101 to treat all forms of epidermolysis bullosa (EB). Paradigm said it plans to submit a new drug application in the latter part of this year. If SD-101 ultimately is approved,…